Published in Am J Hum Genet on December 01, 1997
The fragile X syndrome. J Med Genet (1998) 2.00
Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations. Am J Hum Genet (2000) 1.59
Variants in Deleted in AZoospermia-Like (DAZL) are correlated with reproductive parameters in men and women. Hum Genet (2005) 0.91
Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell (1991) 12.27
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Incidence of premature ovarian failure. Obstet Gynecol (1986) 4.64
Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N Engl J Med (1991) 4.61
The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet (1993) 4.57
DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet (1992) 4.22
Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome. Am J Hum Genet (1995) 2.77
Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. Cell (1994) 2.73
Translational suppression by trinucleotide repeat expansion at FMR1. Science (1995) 2.73
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet (1993) 2.69
Rapid fragile X carrier screening and prenatal diagnosis using a nonradioactive PCR test. JAMA (1993) 2.59
A complex mutable polymorphism located within the fragile X gene. Nat Genet (1993) 2.33
Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet (1994) 2.31
Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet (1991) 2.29
Advances in molecular analysis of fragile X syndrome. JAMA (1994) 1.91
Quantitative comparison of FMR1 gene expression in normal and premutation alleles. Am J Hum Genet (1995) 1.91
Dizygous twinning and premature menopause in fragile X syndrome. Lancet (1994) 1.90
Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet (1997) 1.74
Fragile X syndrome: genetic localisation by linkage mapping of two microsatellite repeats FRAXAC1 and FRAXAC2 which immediately flank the fragile site. J Med Genet (1991) 1.71
Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet (1993) 1.71
Confirmation of early menopause in fragile X carriers. Am J Med Genet (1996) 1.54
FRAXA premutation associated with premature ovarian failure. Am J Med Genet (1996) 1.46
Haplotype and interspersion analysis of the FMR1 CGG repeat identifies two different mutational pathways for the origin of the fragile X syndrome. Hum Mol Genet (1996) 1.27
Survey of the fragile X syndrome and the fragile X E syndrome in a special education needs population. Am J Med Genet (1996) 1.23
Does "incessant" ovulation increase risk for early menopause? Am J Obstet Gynecol (1995) 1.22
Prenatal diagnosis and carrier screening for fragile X by PCR. Am J Med Genet (1996) 1.17
The female and the fragile X. A study of 144 obligate female carriers. Am J Med Genet (1986) 1.15
Characterization of a highly polymorphic dinucleotide repeat 150 KB proximal to the fragile X site. Am J Med Genet (1992) 1.12
FMR1 in global populations. Am J Hum Genet (1996) 1.11
Hotspot for deletions in the CGG repeat region of FMR1 in fragile X patients. Hum Mol Genet (1995) 1.07
Fragile X premutations in familial premature ovarian failure. Lancet (1995) 1.03
Enhanced expression of the murine FMR1 gene during germ cell proliferation suggests a special function in both the male and the female gonad. Hum Mol Genet (1993) 1.00
Triplet repeat expansion mutations: the example of fragile X syndrome. Annu Rev Neurosci (1995) 0.97
Tissue-specific expression of a FMR1/beta-galactosidase fusion gene in transgenic mice. Hum Mol Genet (1995) 0.95
Molecular fragile X screening in normal populations. Am J Med Genet (1996) 0.90
Do mothers of dizygotic twins have earlier menopause? A role for fragile X? Am J Med Genet (1997) 0.88
Examination of factors that influence the expansion of the fragile X mutation in a sample of conceptuses from known carrier females. Am J Med Genet (1996) 0.88
Premature ovarian failure. Current concepts. J Reprod Med (1986) 0.88
The high prevalence of fragile X premutation carrier females: is this frequency unique to the French Canadian population? Am J Hum Genet (1995) 0.78
Investigation of the twinning rate in families with the fragile X syndrome. Am J Med Genet (1988) 0.76
High proportion of twins in carriers of fragile X syndrome. J Med Genet (1992) 0.76
Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell (1991) 12.27
Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell (2001) 8.04
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell (2001) 6.50
Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science (1991) 5.99
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
FMR1 protein: conserved RNP family domains and selective RNA binding. Science (1993) 4.77
Rapid isolation of DNA probes within specific chromosome regions by interspersed repetitive sequence polymerase chain reaction. Genomics (1990) 4.34
Fragile X genotype characterized by an unstable region of DNA. Science (1991) 4.33
DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet (1992) 4.22
Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet (2001) 3.82
FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol Cell (1997) 3.71
Trinucleotide repeat expansion and human disease. Annu Rev Genet (1995) 3.47
Emerin deletion reveals a common X-chromosome inversion mediated by inverted repeats. Nat Genet (1997) 3.30
A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A (1998) 3.26
The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res (2001) 3.18
Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci (1997) 2.93
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst (2001) 2.83
Translational suppression by trinucleotide repeat expansion at FMR1. Science (1995) 2.73
Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. Cell (1994) 2.73
The role of cervical cytology in the declining morbidity and mortality of cervical cancer. Cancer (1974) 2.70
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet (1993) 2.69
Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet (1999) 2.59
Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst (1983) 2.57
The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet (1996) 2.49
The relation of endometriosis to menstrual characteristics, smoking, and exercise. JAMA (1986) 2.22
Tubal infertility and the intrauterine device. N Engl J Med (1985) 2.22
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet (2000) 2.17
The fragile X site in somatic cell hybrids: an approach for molecular cloning of fragile sites. Science (1987) 2.13
Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol Cell Biol (1999) 2.13
Understanding the molecular basis of fragile X syndrome. Hum Mol Genet (2000) 2.13
TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res (2000) 1.98
Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nat Genet (1993) 1.95
Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience (1999) 1.91
Quantitative comparison of FMR1 gene expression in normal and premutation alleles. Am J Hum Genet (1995) 1.91
Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol (1974) 1.86
Prevalence and predictors of depressive symptoms in older premenopausal women: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry (1999) 1.78
Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet (1997) 1.74
Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst (1983) 1.71
Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein. J Biol Chem (1998) 1.63
Elevated spontaneous mutation rate in Bloom syndrome fibroblasts. Proc Natl Acad Sci U S A (1981) 1.62
Are caffeinated beverages risk factors for delayed conception? Lancet (1990) 1.62
Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst (2000) 1.59
Body mass index and ovulatory infertility. Epidemiology (1994) 1.55
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
The influence of lactose consumption on the association of oral contraceptive use and ovarian cancer risk. Am J Epidemiol (1991) 1.52
Fertility and use of cigarettes, alcohol, marijuana, and cocaine. Ann Epidemiol (1993) 1.47
High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome. Hum Mol Genet (1993) 1.42
Relation of tubal infertility to history of sexually transmitted diseases. Am J Epidemiol (1993) 1.38
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer (2008) 1.38
Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer (2001) 1.37
Human genes containing polymorphic trinucleotide repeats. Nat Genet (1992) 1.37
Physical map of human Xq27-qter: localizing the region of the fragile X mutation. Proc Natl Acad Sci U S A (1991) 1.28
Prospective study of talc use and ovarian cancer. J Natl Cancer Inst (2000) 1.28
Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer (1999) 1.26
Early follicular phase hormone levels in relation to patterns of alcohol, tobacco, and coffee use. Fertil Steril (2001) 1.23
Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology (1998) 1.23
Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol (2000) 1.22
Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol (2000) 1.19
Ovarian cancer and talc: a case-control study. Cancer (1982) 1.19
Re-examination of factors associated with expansion of CGG repeats using a single nucleotide polymorphism in FMR1. Hum Mol Genet (1998) 1.18
Association of the mouse infertility factor DAZL1 with actively translating polyribosomes. Biol Reprod (2000) 1.18
Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol (1997) 1.16
Gonadal mosaicism and genetic counseling for X-linked recessive lethals. Am J Hum Genet (1974) 1.14
Infertility in women and moderate alcohol use. Am J Public Health (1994) 1.14
Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J Biol Chem (2000) 1.13
Epidemiologic determinants of endometriosis: a hospital-based case-control study. Ann Epidemiol (1997) 1.12
FMR1 in global populations. Am J Hum Genet (1996) 1.11
Further localization of X-linked hydrocephalus in the chromosomal region Xq28. Am J Hum Genet (1992) 1.11
Actin-binding protein (ABP-280) filamin gene (FLN) maps telomeric to the color vision locus (R/GCP) and centromeric to G6PD in Xq28. Genomics (1993) 1.10
Molecular evidence for true isochromosome 21q. Hum Genet (1988) 1.10
The relationship of tubal infertility to barrier method and oral contraceptive use. JAMA (1987) 1.09
Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. Int J Cancer (2000) 1.08
Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med (1982) 1.06
Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod (2013) 1.06
Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res (1996) 1.05
Ethnic background and in vitro fertilization outcomes. Int J Gynaecol Obstet (2005) 1.05
Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol (1984) 1.04
The effect of FMR1 CGG repeat interruptions on mutation frequency as measured by sperm typing. J Med Genet (1997) 1.04
Assignment of the creatine transporter gene (SLC6A8) to human chromosome Xq28 telomeric to G6PD. Genomics (1995) 1.03
Four chromosomal breakpoints and four new probes mark out a 10-cM region encompassing the fragile-X locus (FRAXA). Am J Hum Genet (1991) 1.03
Identification of mouse YB1/p50 as a component of the FMRP-associated mRNP particle. Biochem Biophys Res Commun (2000) 1.03
Fragile X CGG repeat structures among African-Americans: identification of a novel factor responsible for repeat instability. Hum Mol Genet (2000) 1.02
Survey of the fragile X syndrome CGG repeat and the short-tandem-repeat and single-nucleotide-polymorphism haplotypes in an African American population. Am J Hum Genet (2000) 1.02
Predictive value of serum and follicular fluid leptin concentrations during assisted reproductive cycles in normal women and in women with the polycystic ovarian syndrome. Hum Reprod (2000) 1.01
Statistical methods in evaluating the outcome of infertility therapy. Fertil Steril (1979) 1.01
Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol (1992) 1.01
Polyalanine expansion in synpolydactyly might result from unequal crossing-over of HOXD13. Science (1997) 1.01
Maternal exposure to second-hand tobacco smoke and pregnancy outcome among couples undergoing assisted reproduction. Hum Reprod (2006) 1.01
Trinucleotide repeat instability: when and where? Nat Genet (1993) 1.00
Aberrant protein deposition and neurological disease. J Biol Chem (1999) 1.00
Normal variation at the myotonic dystrophy locus in global human populations. Am J Hum Genet (1995) 1.00
Assignment of X-linked hydrocephalus to Xq28 by linkage analysis. Genomics (1990) 0.99
Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965 to 1985. Obstet Gynecol (1987) 0.98
Isolation and characterization of human factor IX cDNA: identification of Taq I polymorphism and regional assignment. Somat Cell Mol Genet (1984) 0.97
Review of epidemiologic studies of endometrial cancer and exogenous estrogen. Obstet Gynecol (1979) 0.96
Nuclease sensitivity of permeabilized cells confirms altered chromatin formation at the fragile X locus. Somat Cell Mol Genet (1996) 0.96
Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (1998) 0.96
Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum Reprod (1999) 0.95
Trends in the incidence of endometrial cancer in the United States. Gynecol Oncol (1974) 0.94